Document is current
Any future updates will be listed below
-
Authors
Cattaneo, Chiara M.
Battaglia, Thomas
Urbanus, Jos https://orcid.org/0000-0003-3074-8477
Moravec, Ziva
Voogd, Rhianne
de Groot, Rosa
Hartemink, Koen J. https://orcid.org/0000-0003-4282-1096
Haanen, John B. A. G.
Voest, Emile E. https://orcid.org/0000-0001-8249-9586
Schumacher, Ton N. https://orcid.org/0000-0003-0517-8804
Scheper, Wouter https://orcid.org/0000-0003-1555-587X
- License Information
-
More Information
Article History
Received: 24 February 2021
Accepted: 6 October 2022
First Online: 2 January 2023
Competing interests
: T.N.S. is advisor for Allogene Therapeutics, Celsius, Merus, Neogene Therapeutics and Scenic Biotech; is a recipient of research support from Merck KgaA; is a stockholder in Allogene Therapeutics, Cell Control, Celsius, Merus, Neogene Therapeutics and Scenic Biotech and is venture partner at Third Rock Ventures, all outside of the current work. J.B.A.G.H. is advisor for BioNTech, Neogene Therapeutics, Scenic Biotech and T-Knife; is a recipient of research grant support from BioNTech; is a stock option holder in Neogene Therapeutics, all outside of the current work. All other authors declare no competing interests.
